Overview

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2021-10-12
Target enrollment:
Participant gender:
Summary
To evaluate the safety and tolerability of subcutaneous (SC) dose administrations of Efavaleukin Alfa in participants with systemic lupus erythematosus (SLE).
Phase:
Phase 1
Details
Lead Sponsor:
Amgen